119 related articles for article (PubMed ID: 8747399)
1. Molecular approaches to prevention and detection of epithelial ovarian cancer.
Bast RC; Boyer CM; Xu FJ; Wiener J; Dabel R; Woolas R; Jacobs I; Berchuck A
J Cell Biochem Suppl; 1995; 23():219-22. PubMed ID: 8747399
[TBL] [Abstract][Full Text] [Related]
2. Prevention and early detection of ovarian cancer: mission impossible?
Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
[TBL] [Abstract][Full Text] [Related]
3. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
4. Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.
Fujiwara K; McAlpine JN; Lheureux S; Matsumura N; Oza AM
Am Soc Clin Oncol Educ Book; 2016; 35():e247-57. PubMed ID: 27249730
[TBL] [Abstract][Full Text] [Related]
5. Cell growth regulation in epithelial ovarian cancer.
Bast RC; Boyer CM; Jacobs I; Xu FJ; Wu S; Wiener J; Kohler M; Berchuck A
Cancer; 1993 Feb; 71(4 Suppl):1597-601. PubMed ID: 8431895
[TBL] [Abstract][Full Text] [Related]
6. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
7. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
8. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
9. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer screening.
van Nagell JR; DePriest PD; Gallion HH; Pavlik EJ
Cancer; 1993 Feb; 71(4 Suppl):1523-8. PubMed ID: 8431889
[TBL] [Abstract][Full Text] [Related]
11. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of human ovarian cancer.
Chow SN; Chien CH; Chen CT
Int Surg; 1996; 81(2):152-7. PubMed ID: 8912082
[TBL] [Abstract][Full Text] [Related]
13. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
[TBL] [Abstract][Full Text] [Related]
14. Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer.
Baker VV
J Cell Biochem Suppl; 1995; 23():243-6. PubMed ID: 8747404
[TBL] [Abstract][Full Text] [Related]
15. Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis.
Xu J; Zheng T; Hong W; Ye H; Hu C; Zheng Y
Cell Physiol Biochem; 2018; 50(1):214-232. PubMed ID: 30336465
[TBL] [Abstract][Full Text] [Related]
16. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
17. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Wu S; Boyer CM; Whitaker RS; Berchuck A; Wiener JR; Weinberg JB; Bast RC
Cancer Res; 1993 Apr; 53(8):1939-44. PubMed ID: 8385577
[TBL] [Abstract][Full Text] [Related]
19. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
